Novo Nordisk to Unveil Semaglutide Data and Next-Gen Amylin Treatments at EASD 2026 — Novo Nordisk

Event summary

Novo Nordisk will present 44 abstracts at EASD 2026, including real-world data on Wegovy® pill and CagriSema research on appetite regulation and body composition.
Key presentations include fMRI data on CagriSema's effects on eating behavior and brain responses to food cues.
Data on semaglutide's impact on liver fat in obesity and cardiovascular outcomes in type 2 diabetes will also be shared.
EASD 2026 runs from September 28 to October 2 in Milan, Italy.

The big picture

Novo Nordisk's presentation at EASD 2026 underscores its strategic focus on expanding the evidence base for semaglutide across multiple cardiometabolic conditions. The company is positioning itself to lead in the treatment of interconnected diseases like obesity, type 2 diabetes, and liver-related outcomes. The breadth of data being shared highlights Novo Nordisk's ambition to shape the next generation of cardiometabolic care, potentially influencing market dynamics and regulatory pathways.

What we're watching

Pipeline Progress: The pace at which Novo Nordisk's next-generation amylin treatments advance through clinical trials will determine their competitive positioning in the cardiometabolic space.
Regulatory Approvals: Whether the real-world evidence presented at EASD 2026 accelerates regulatory approvals for Wegovy® pill and other semaglutide formulations.
Market Adoption: How the new data on appetite regulation and body composition influences market adoption of Novo Nordisk's treatments for obesity and type 2 diabetes.